Patents by Inventor Natalio Vita

Natalio Vita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-13 receptor antibodies
    Patent number: 8318910
    Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and uses thereof.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: November 27, 2012
    Assignee: Sanofi
    Inventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
  • IL-13 RECEPTOR ANTIBODIES
    Publication number: 20110201029
    Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and uses thereof.
    Type: Application
    Filed: February 15, 2011
    Publication date: August 18, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Daniel CAPUT, Pascual FERRARA, Patrick LAURENT, Natalio VITA
  • Purified polypeptides having IL-13 receptor activity
    Patent number: 7928073
    Abstract: This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: April 19, 2011
    Assignee: Sanofi-Aventis
    Inventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
  • Purified polypeptides having IL-13 receptor activity
    Publication number: 20060035856
    Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and/or IL13 receptor ? and uses thereof.
    Type: Application
    Filed: July 15, 2005
    Publication date: February 16, 2006
    Applicant: sanofi-aventis
    Inventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
  • Purified polypeptides having IL-13 receptor activity
    Publication number: 20060035855
    Abstract: This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4.
    Type: Application
    Filed: July 15, 2005
    Publication date: February 16, 2006
    Applicant: sanofi-aventis
    Inventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
  • Purified polypeptides having IL-13 receptor activity
    Publication number: 20050282216
    Abstract: This invention relates to a purified polypeptide, comprising an amino acid sequence chosen from: a) the sequence SEQ ID No. 2, b) any biologically active sequence derived from SEQ ID No. 2.
    Type: Application
    Filed: July 18, 2005
    Publication date: December 22, 2005
    Applicant: sanofi-aventis
    Inventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
  • Type-2 neurotensin receptor (NT-R2)
    Patent number: 6274333
    Abstract: This invention relates to a purified polypeptide which constitutes the type-2 neurotensin receptor (NT-R2), as well as the nucleotide sequence encoding this polypeptide.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: August 14, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Daniel Caput, Pascale Chalon, Pascual Ferrara, Natalio Vita
  • Type-2 neurotensin receptor (NT-R2)
    Patent number: 6022856
    Abstract: This invention relates to a purified polypeptide which constitutes the type-2 neurotensin receptor (NT-R2), as well as the nucleotide sequence encoding this polypeptide.
    Type: Grant
    Filed: May 19, 1997
    Date of Patent: February 8, 2000
    Assignee: Sanofi
    Inventors: Daniel Caput, Pascale Chalon, Pascual Ferrara, Natalio Vita
  • Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
    Patent number: 6001649
    Abstract: A new chemotactic cytokine, NC28 or Monocyte Chemotactic Protein-3 (MCP-3), is provided. Fragments of the cytokine comprising its 13 C-terminal amino acids also exhibit chemotactic activity. The polypeptides may be used as anticancer agents or immunomodulators. DNA encoding the NC28/MCP-3 polypeptides, as well as corresponding vectors and recombinant expression systems, are also provided.
    Type: Grant
    Filed: September 29, 1992
    Date of Patent: December 14, 1999
    Assignee: Societe Anonyme: Elf Sanofi
    Inventors: Daniel Caput, Pascual Ferrara, Brigitte Miloux, Adrian Minty, Natalio Vita
  • Drugs containing a glycosylated interleukin-2
    Patent number: 5417970
    Abstract: An interleukin-2 preparation suitable for pharmaceutical purposes, consisting essentially of disialilated glycosylated interleukin-2, monosialilated glycosylated interleukin-2, or a mixture thereof, and substantially free of organic solvents, is isolated from recombinant CHO cells transformed with a vector containing a DNA sequence coding for a natural precursor of human interleukin-2, and is purified by a multi-step process.
    Type: Grant
    Filed: November 16, 1993
    Date of Patent: May 23, 1995
    Assignee: Sanofi
    Inventors: Willem Roskam, deceased, Bertrand Basuyaux, Pascual Ferrara, Martine Laporte, Thierry Maureaud, Natalio Vita, Alain Bayol, Genevieve Perry